Capasso Planning Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$484K Hold
526
0.26% 47
2025
Q4
$565K Sell
526
-284
-35% -$272K 0.31% 40
2025
Q3
$618K Sell
810
-619
-43% -$461K 0.38% 39
2025
Q2
$1.11M Sell
1,429
-417
-23% -$324K 0.63% 26
2025
Q1
$1.53M Sell
1,846
-184
-9% -$153K 0.64% 33
2024
Q4
$1.57M Sell
2,030
-1,001
-33% -$829K 0.63% 32
2024
Q3
$2.69M Sell
3,031
-196
-6% -$176K 0.79% 23
2024
Q2
$2.92M Buy
3,227
+2,818
+689% +$2.25M 0.95% 24
2024
Q1
$318K Sell
409
-8
-2% -$5.69K 0.13% 84
2023
Q4
$243K Buy
417
+3
+0.7% +$1.75K 0.11% 91
2023
Q3
$222K Buy
+414
New +$213K 0.12% 88

Other funds holding LLY

Capasso Planning Partners's LLY Position: Q1 2026 in Review

Capasso Planning Partners held its Eli Lilly (LLY) position steady in Q1 2026 at 526 shares worth $484K. The position accounts for 0.26% of the portfolio, ranked #47.

Capasso Planning Partners first reported a position in LLY in Q3 2023 and has held it in 11 quarters since. The position peaked at $2.92M in Q2 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Capasso Planning Partners held 526 shares of Eli Lilly worth $484K as of Q1 2026.
  • Capasso Planning Partners left its Eli Lilly share count unchanged in Q1 2026.
  • Eli Lilly made up 0.26% of Capasso Planning Partners's portfolio in Q1 2026, its #47 holding.
  • Capasso Planning Partners first reported a position in Eli Lilly in Q3 2023 and has held it in 11 quarters since.
  • Capasso Planning Partners's Eli Lilly position peaked at $2.92M in Q2 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Capasso Planning Partners's 13F filing for Q1 2026, filed 27 May 2026.